Rosa L. de Jager

Rosa L. de Jager

Auto-generated profile, based on publicly available information

Rosa L. de Jager

Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
RJRosa L. de Jager
Rosa L. de Jager
EMErik M. van Maarseveen
Erik M. van Maarseveen
MBMichiel L. Bots
Michiel L. Bots
PBPeter J Blankestijn
Peter J Blankestijn
OIon behalf of the SYMPATHY investigators
on behalf of the SYMPATHY investigators

22 June 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RJRosa L de Jager
Rosa L de Jager
NCNiek F. Casteleijn
Niek F. Casteleijn
EBEsther de Beus
Esther de Beus
MBMichiel L Bots
Michiel L Bots
EVEvert-Jan E Vonken
Evert-Jan E Vonken
PBPeter J Blankestijn
Peter J Blankestijn
Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause chronic severe kidney-related pain. Multidisciplinary programmes and surgical methods have shown inconsistent results with respect to pain reduction. Percutaneous catheter-based renal denervation (RDN) could be a less invasive treatment option for these patients. Our aim was to explore the change in perceived pain and use of analgesic medication from baseline to 3, 6 and 12 months after RDN. Patients with LPHS or ADPKD, who experienced kidney-related pain ≥3 months with a visual analogue scale (VAS) score ≥ 50/100 could be included. Percutaneous RDN was performed with a single-electrode radiofrequency ablation catheter. RDN was performed in 11 patients (6 with LPHS and 5 with ADPKD). Perceived pain declined in the whole group by 23 mm (P = 0.012 for the total group). In patients with LPHS and ADPKD, the median daily defined dosage of analgesic medication decreased from 1.6 [interquartile range (IQR) 0.7–2.3] and 1.4 (IQR 0.0–7.4) at baseline to 0.3 (IQR 0.0–1.9; P = 0.138) and 0.0 (IQR 0.0–0.8; P = 0.285) at 12 months, respectively. Mean estimated glomerular filtration rate decreased in the whole group by 5.4 mL/min/1.73 m2 at 6 months compared with baseline (P = 0.163). These results suggest that percutaneous catheter-based RDN reduces pain complaints and the use of analgesic medication in patients with LPHS or ADPKD. The present results can serve as the rationale for a larger, preferably randomized (sham) controlled study.